US President Donald Trump has signed an executive order attempting to restore a robust domestic manufacturing base for prescription drugs in the USA.
The order directs the US Food and Drug Administration (FDA) to reduce the amount of time it takes to approve domestic pharmaceutical manufacturing plants by eliminating duplicative and unnecessary requirements, streamlining reviews and working with domestic manufacturers to provide early support before facilities come online.
To hinder competition from overseas, the order directs the FDA to increase fees for and inspections of foreign manufacturing plants and to improve enforcement of active pharmaceutical ingredient source reporting by foreign drug producers, and consider publicly displaying a list of facilities that do not comply.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze